Feb. 15, 2022

Company: Chiome Bioscience Inc.

Representative: Shigeru Kobayashi, President & CEO

(Code: 4583, Tokyo Stock Exchange Mothers)

License agreement for a diagnostic kit with Fujirebio, Inc.

Chiome Bioscience Inc.("Chiome") and Fujirebio, Inc. ("Fujirebio") entered into a license agreement where Fujirebio will commercialize a diagnostic kit containing specific antibodies that were generated by Chiome's ADLibⓇ system (Chiome's proprietary technology generating diversified antibodies).

The diagnostic kit is for analysis of some drug in the body. This program was conducted by Fujirebio under the license and collaborative research agreement that was originally signed as of September 30, 2010. This product is the third achievemnet resulted from the collaboration, the first one is the diagnostic kit for Vitamin D, and the second one is for aldosterone. Chiome will receive the pre-determined royalty based on the sales of this product.

This conclusion expects only minor impact on the financial performance in the fiscal period ending December 31, 2022.

【Inquiries】

Chiome Bioscience Inc. Investor Relations E-mail : ir@chiome.co.jp

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Chiome Bioscience Inc. published this content on 15 February 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 February 2022 06:16:11 UTC.